Updated on 17 June 2013
"The United States is now the only developed country to take such a restrictive view of patent eligibility, signaling an unjustified indifference towards our global economic and scientific leadership in the life sciences," BIO said.
Commenting on the judgement, Life Sciences Industry Analyst Justin Collishaw has said, "The decision to prohibit patent protection of human genes was accompanied by a decision to allow patent protection of synthetic versions of gene material. This is the positive news for companies developing diagnostic tests or gene therapies. In summary, multiple companies can develop gene therapies or diagnostic tests for identical sets of genes; however, a unique diagnostic test for a gene or a unique therapy used to alter or supplement particular genes is considered "synthetic gene material," lending to patent protection."